An Overlooked Crisis in Hospitals Could Be Pharma’s Next Great Opportunity
With an innovative technology addressing a crucial infection-prevention challenge, PolyPid’s technology could shift hospital incentives – and its ~$50M current market cap may position it as a bargain given it’s already validated with positive phase 3 results

